Earnings ·
Teva Pharmaceutical Industries Ltd. reported second quarter 2026 revenues of $4.1 billion, a 1% decrease…
TEVATeva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. reported second quarter 2026 revenues of $4.1 billion, a 1% decrease year-over-year in U.S. dollars, driven by lower generic sales from lenalidomide capsules offset by strong growth in innovative brands AUSTEDO and AJOVY. The company recorded a GAAP loss per share of $0.49, including $726 million in expenses related to the acquisition of Emalex Biosciences for its Tourette syndrome therapy ecopipam. Teva raised its 2026 revenue outlook to $16.5–$16.85 billion and announced a transition from American Depositary Shares to direct ordinary share listing on the NYSE, effective September 14, 2026. The company operates in the global pharmaceutical industry, specializing in generic medicines, biosimilars, and innovative biopharmaceuticals.